About 2.1 percent of patients treated with Xarelto compared with 1.8 percent to 3 percent of patients treated with the enoxaparin and VKA combination experienced a recurrent DVT or PE.
FORBES: Rivaroxaban Gains FDA Indications For The Treatment And Prevention Of DVT And PE